日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term follow-up of children who received rapid genomic sequencing

对接受快速基因组测序的儿童进行长期随访

Sanford Kobayashi, Erica; Tobin, Laura E; Arenchild, Madison; Benson, Wendy; Coufal, Nicole G; Juarez, Edwin F; Kingsmore, Stephen F; Knight, Jason; Lenberg, Jerica; Schwarz, Adam; Vargas-Shiraishi, Ofelia; Wigby, Kristen; Bainbridge, Matthew

The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors

USP1 抑制剂 KSQ-4279 克服了同源重组缺陷肿瘤中的 PARP 抑制剂耐药性

Louise Cadzow, Jehrod Brenneman, Erica Tobin, Pamela Sullivan, Sumeet Nayak, Janid A Ali, Sol Shenker, Jim Griffith, Michael McGuire, Paula Grasberger, Yuji Mishina, Morgan Murray, Anne E Dodson, Hugh Gannon, Elsa Krall, Jeff Hixon, Edmond Chipumuro, Kerstin Sinkevicius, Prafulla C Gokhale, Suthakar

Mediation of 6-year mid-childhood follow-up outcomes after pre-school social communication (PACT) therapy for autistic children: randomised controlled trial

自闭症儿童接受学前社交沟通(PACT)疗法后,6 年中期儿童随访结果的中介作用:随机对照试验

Carruthers, Sophie; Pickles, Andrew; Charman, Tony; McConachie, Helen; Le Couteur, Ann; Slonims, Vicky; Howlin, Patricia; Collum, Rachel; Salomone, Erica; Tobin, Hannah; Gammer, Isobel; Maxwell, Jessica; Aldred, Catherine; Parr, Jeremy; Leadbitter, Kathy; Green, Jonathan

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

发现 AG-120 (Ivosidenib):用于治疗 IDH1 突变型癌症的同类首创突变型 IDH1 抑制剂

Janeta Popovici-Muller, René M Lemieux, Erin Artin, Jeffrey O Saunders, Francesco G Salituro, Jeremy Travins, Giovanni Cianchetta, Zhenwei Cai, Ding Zhou, Dawei Cui, Ping Chen, Kimberly Straley, Erica Tobin, Fang Wang, Muriel D David, Virginie Penard-Lacronique, Cyril Quivoron, Véronique Saada, Stép